![]() |
FDA Makes Label Changes to Statins...
March 1, 2012 - Clinical , In the News / Politics By: Mohamed Dungersi – On February 28, the U.S. Food and Drug Administration (FDA) approved important safety label changes for the class of cholesterol-lowering drugs known as statins. Aligned with the FDA’s goal to provide the public with more information for the safe and effective use of statins, the agency made several modifications to the… |
![]() |
Inhaled Caffeine Under Investigation...
March 1, 2012 - Featured , In the News / Politics By: Mahdieh Danesh Yazdi – A few months ago, a new product called AeroShot Pure Energy hit the markets in New York and Massachusetts. AeroShot is a new inhaler that gives the user bursts of caffeine. Each inhaler contains an estimated 100mg of caffeine, approximately the same amount as a large cup of coffee. It… |
![]() |
Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support. The main cause of this decreased BMD is inadequate calcium intake or absorption. The decreased BMD can cause diffuse lesions throughout the skeletal system and can… |
![]() |
The Latest Novartis Recalls...
February 1, 2012 - In the News / Politics By: Aleena Chacko, Long Island University Pharm.D. Candidate c/o 2013 – Established in 1996, Novartis International AG is a multinational pharmaceutical company based in Switzerland. On January 8, 2012, Novartis issued a recall on some popular over the counter (OTC) medications in the United States (U.S.) over concerns about broken or incorrect tablets ending up… |
![]() |
Bydureon®: A Weekly Injection for Type 2 Diabetes Mell...
February 1, 2012 - Clinical , Featured , In the News / Politics By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise. Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide). It is the first once-a-week medication for T2DM in the market.… |
![]() |
Should Plan B Have an Age Restriction?...
February 1, 2012 - Professional Advice / Opinions By: Marie Huang – Back in December, the FDA was overruled by the presidential administration to make Plan B (levonorgestrel 1.5 mg) an over-the-counter (OTC) medication.1 We became interested in the matter, and asked our fellow students if Plan B should be available to people of all ages directly off of drugstore / supermarket shelves… |
![]() |
New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1 Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.… |
![]() |
FDA Challenges Pharmacists’ Right to Compound...
January 1, 2012 - Featured , In the News / Politics By: Ebey P. Soman – With clearly established roles for pharmacists, compounding is recognized and upheld as a core foundation of the pharmacy profession. It allows pharmacists to provide unique and tailored medication regimens for their patients. The U.S. Food and Drug Administration (FDA) thought otherwise when the agency sued Franck’s Lab, Inc., a Florida-based… |
![]() |
Liposomal Doxorubicin For Liver Cancer...
January 1, 2012 - Clinical By Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Over the last two decades, there has been an increasing focus on hepatocellular carcinoma (HCC, most commonly known as liver cancer). In the United States, as of 2011, there have been an estimated 26,190 new cases and 19,590 deaths from both hepatic and intrahepatic bile duct cancer. Defined by the… |
![]() |
FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans. Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack. On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for… |
![]() |
Placement of Carisoprodol into Schedule IV...
January 1, 2012 - In the News / Politics By Jena Marion, Pharm.D. Candidate c/o 2013 – On December 12, 2011, the Administrator of the Drug Enforcement Agency (DEA) ruled to place carisoprodol (Soma®) into Schedule IV of the Controlled Substances Act (CSA). Carisoprodol has been in use since it was approved for marketing in the U.S. in 1959 with the indication of “relief… |
![]() |
Xigris: A Worldwide Withdrawal...
January 1, 2012 - Clinical , In the News / Politics By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients. Drotrecogin alfa is a recombinant form of human activated protein C. The efficacy of drotrecogin alfa was… |
![]() |
Differences Between Antagonists and Inverse Agonists...
December 1, 2011 - Clinical By: Neal Shah – There are two major classifications of drug-receptor activity: agonism and antagonism. Agonism occurs when a molecule binds to a receptor, causes an exertion of normal receptor operation, and eventually causes a response. Antagonism of a receptor occurs when a molecule binds to the receptor and does not allow activity to occur.1… |
![]() |
Finding Your Niche in Pharmacy...
December 1, 2011 - Professional Advice / Opinions By: Nandini Puranprashad – As primary advocators of patient care, student pharmacists and pharmacists are well on their way in changing the public’s impression of us staying behind the counter at the corner drugstore doing nothing but “counting, licking, and sticking.” It is time to step out of the classroom and from behind the counters… |
![]() |
Drug Shortages: Impacts and Prevention Measures...
December 1, 2011 - Featured , In the News / Politics , Professional Advice / Opinions By: Jimmy Johnson, PharmD Candidate c/o 2012 – Drug shortages have become more and more of an issue in the health care industry. There are over 200 drugs on the Food and Drug Administration’s (FDA) drug shortage list – a number that has tripled in the last five years.1 The largest impact has been on anesthesia… |
![]() |
Faculty Spotlight: Dr. Charles R. Ashby...
December 1, 2011 - Featured , Professional Advice / Opinions By: Neal Shah – Dr. Ashby is a well-known Pharmacology professor for student pharmacists studying in their professional years. He graduated from the University of Louisville with a BA in Biology and Psychology in 1983. After obtaining his PhD in Pharmacology from the University of Louisville in 1987, he continued his education by obtaining a… |
![]() |
Federal Government to Attempt Limiting Drug Shortages...
December 1, 2011 - In the News / Politics By: Mahdieh Danesh Yazdi, with special thanks to Dr. Tomasz Jodlowski – Drug shortages have plagued health care institutions in recent years; they present a serious problem to health care delivery on a national scale. In 2004, there were 58 drug shortages; now, in 2011, this number has increased to 198. Due to limited access… |
![]() |
Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte… |
![]() |
In The News: TNF-Alpha Inhibitors Receive More Warnings...
October 1, 2011 - In the News / Politics By Ebey P. Soman – TNF-alpha inhibitors are drugs used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, as well as other disease states. These agents suppress the immune system and increase the risk of developing serious infections. Currently, there are five approved drugs in this category: • Adalimumab (Humira®, Abbott) • Certolizumab pegol… |